Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine

Journal of Human Hypertension

Volumn 21, Issue 5, 2007, Pages 374-380

  Weycker, D ^a   Edelsberg, J ^a   Vincze, G ^b   Kjeldsen, S E ^c,d   Jamerson, K ^c   Khan, Z M ^b   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; VALSARTAN;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VALINE;

EID: 34247343986     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002159     Document Type: Article

References (17)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States: 1999-2000. Hypertension 2004; 44: 398-404.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
3. Kannel WB. Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertension 2000; 13: 3S-10S.
4. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type II diabetes mellitus. N Engl J Med 2000; 342: 905-912.
5. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275: 1571-1576.
6. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB et al. Population-based incidence rates and risk factors for type II diabetes in white individuals. Diabetes 2004; 53: 1782-1789.
7. Verdecchia. P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al.. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
8. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type II diabetes. Diabetes Care 2005; 28: 736-744.
9. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
11. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA et al. Effects of valsartan compared to amlodipine on preventing type II diabetes in high risk hypertensive patients: The VALUE trial. J Hypertens 2006; 24: 1405-1412.
12. Cardinal H, Tahami Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: A generalizability issue. Can J Cardiol 2004; 20: 417-421.
13. Health Insurance Portability and Accountability Act of 1996, 42 USC 1§320-d2. Available at: http://www.cms.hhs.gov/hipaageninfo/downloads/hipaalaw.pdf (accessed September 5, 2006).
14. Public Welfare - Protection of Human Subjects; 45CFR 46 4§6.101. Available at: http://ohsr.od.nih.gov/guidelines/45cfr4 (accessed September 5, 2006).
15. Julius S, Gudbrandsson T, Jamerson KA, Tariq SS, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-986.
16. Carlsson P-O, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133.
17. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type II diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.